Developing a new type of HIV vaccine using mRNA technology
Project 2 - GMP Manufacturing of mRNA Immunogens
This study is working on a new HIV vaccine using cutting-edge mRNA technology to help your body fight the virus better, and if you're eligible, you might get a chance to join the first round of testing it out!
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10547805 on NIH RePORTER |
What this research studies
This research focuses on creating a next-generation HIV vaccine that utilizes messenger RNA (mRNA) technology to produce immunogens. The approach aims to overcome current challenges in vaccine development by using nucleoside-modified mRNA encapsulated in lipid nanoparticles, which may enhance safety and immunogenicity. The project will manufacture specific mRNA immunogens designed to induce immune responses and will eventually lead to a Phase I clinical trial. Patients may have the opportunity to participate in this trial if they meet the eligibility criteria.
Who could benefit from this research
Good fit: Ideal candidates for participation would be individuals at risk for HIV or those who are HIV-negative and interested in vaccine trials.
Not a fit: Patients who are already HIV-positive or those with contraindications to mRNA vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective HIV vaccine that generates strong and lasting immune responses.
How similar studies have performed: While mRNA technology is relatively novel in the context of HIV vaccines, it has shown success in other vaccine developments, particularly during the COVID-19 pandemic.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Denny, Thomas — Duke University
- Study coordinator: Denny, Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.